Clinical Trial Search

Primary: Proportion of Participants With no Evidence of Cervical Dysplasia at 12-months — 0.66 proportion of participants

Primary: Objective Response Rate — 4; 7; 13; 32 Participants

Primary: Number of Participants Who Set A Target Quit Date (TQD) and Complete Phone Counseling — 14; 14; 14 Participants — p=0.4137

Primary: Percentage of Participants Without Treatment Failure During 2-Years of Observation — 59.2; 53.5; 53.5; 61.1 Percentage of participants

Primary: Number of Participants Experiencing Dose Limiting Toxicities — 0; 1; 7 Participants

Primary: Glucose Uptake in Leg Muscles — 6.3; 16.4 Percentage (%)

Primary: Change in Motor Function Score as Assessed by Modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III — 0.72; 0.01 score on a…

Primary: Primary Efficacy for MGD: Change From Baseline to Month 4 in Meibum Gland Secretion Score (MGS). — 12.1; 16 Units on the Meibomian Gland Score scale

Primary: Number of Participants With Appropriate Treatment — 31; 23 Participants — p=0.45

Primary: Change in Peak Aerobic Capacity — 17.1; 16.8; 17.9; 15.9 ml/kg/min

Primary: Mastery Scale — 21.65; 18.91; 22.13; 19.2 units on a scale — p=0.36

Primary: Primary Efficacy for MGD: Change From Baseline to Month 3 in Meibomian Gland Secretion Score (MGS) — 12.8; 8.8 Units on the MGS Scale

Primary: Table 2. Comparison of 4 Groups — -2.54; -1.49; -2.27; -1.52 units on a scale — p=0.1860

Primary: Number of Subjects With Drug-related Adverse Events — 2; 1; 2; 1 Participants

Primary: Rod and Disk Test (RDT) Mean Performance — 17; 13.3; 7.8; 12.1 degrees